Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Sep;22(9):e380.
doi: 10.1016/S1470-2045(21)00478-2.

Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer - Authors' reply

Arjun V Balar  1 , Ashish M Kamat  2 , Ronald de Wit  3 ; KEYNOTE-057 investigators
Affiliations
Comment

Pembrolizumab monotherapy for high-risk, non-muscle invasive bladder cancer - Authors' reply

Arjun V Balar et al. Lancet Oncol. 2021 Sep.
No abstract available

PubMed Disclaimer

Conflict of interest statement

AVB reports research funding from AstraZeneca/MedImmune, Genentech/Roche, Merck Sharp & Dohme, and Seattle Genetics; has been a consultant to AstraZeneca/MedImmune, Cerulean Pharma, Genentech/Roche, Incyte, Merck Sharp & Dohme, Pfizer/EMD Serono, and Seattle Genetics/Astellas; and honoraria from AstraZeneca/MedImmune, Genentech/Roche, and Merck Sharp & Dohme. AMK reports research funding from FKD Industries and Merck Sharp & Dohme; honoraria from UroToday Publishing and EAU (EU Oncology); has been a consultant to Merck Sharp & Dohme, Bristol Myers Squibb, Imagin, Eisai, Arquer, MDX Health, Photocure, AstraZeneca, Tesaro, Abbott Molecular, US Biotest, Ferring, and BioClinica; travel expenses from Pfizer Japan; holds patents for CyPRIT-Cytokine Panel for Response to Intravesical Immunotherapy; and is the president of the International Bladder Cancer Group and the International Bladder Cancer Network. RdW reports research funding from Bayer and Sanofi; has been a consultant to Astellas, Merck Sharp & Dohme, Roche/Genentech, and Sanofi; and honoraria from Astellas, Bayer, Janssen, Merck Sharp & Dohme, Roche/Genentech, and Sanofi.

Comment on

MeSH terms

Substances

LinkOut - more resources